| HOME >> BIOLOGY >> TECHNOLOGY |
Selling, general and administrative expenses increased to $309.0 million for the nine months ended September 30, 2008, from $268.6 million for the same period in 2007. The increase reflects costs associated with the Company's expanded field force, increased promotional activities for BYETTA and SYMLIN, investments in market development activities for exenatide once weekly and increases in business infrastructure.
Research and development expenses increased to $226.1 million for the nine months ended September 30, 2008, from $192.7 million for the same period in 2007. The increase primarily reflects increased development expenses for exenatide once weekly and continued investment in the Company's obesity programs. Non-GAAP, research and development expenses net of cost sharing payments increased to $172.1 million for the quarter ended September 30, 2008 compared to $158.7 million for the same period in 2007.
Collaborative profit sharing was $229.4 million for the nine months ended September 30, 2008, compared to $212.3 million for the same period in 2007.
Net loss was $211.3 million, or $1.54 per share for the nine months ended September 30, 2008, compared to $134.2 million, or $1.02 per share, for the same period in 2007.
Conference Call
Amylin will Webcast its Quarterly Update Conference Call today at 5:00
p.m. ET/2:00 p.m. PT. The call will be Webcast live through Amylin's
corporate Web site, http://www.amylin.com, and a recording will be made available
following the close of th
'/>"/>
| SOURCE Amylin Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |